Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Umeclidinium/vilanterol (UMEC/VI) demonstrated strong effectiveness in improving FEV1, ranking second with a SUCRA (surface under cumulative rankings) score of 93.5%, and showed statistically significant greater improvements in FEV1 at 24 weeks compared to all dual and mono-bronchodilator comparators, with an E(max) of 0.185 L.
• In patients with stable COPD (chronic obstructive pulmonary disease), UMEC/VI provided similar improvements in the St. George's Respiratory Questionnaire (SGRQ) total score compared to other long-acting muscarinic antagonists (LAMAs) / long-acting beta2-agonists (LABAs) combinations and significantly greater improvements compared to several monotherapies, while also reducing rescue medication use and improving outcomes in annualized moderate/severe exacerbation rates.
• For patients with moderate-to-severe COPD, LABA/LAMA combinations, including UMEC/VI, were found to be more effective than ICS/LABA fixed-dose combinations in improving FEV1.
• The rate of adverse events (AEs) between umeclidinium/vilanterol (UMEC/VI) and tiotropium (TIO) was not significant, indicating comparable safety profiles, while different LABA/LAMA fixed-dose combinations (FDCs) and placebo showed similar outcomes regarding mortality, serious adverse events (SAEs), and withdrawals due to AEs.
• There were no significant differences among LAMA/LABA combinations, including UMEC/VI, in terms of moderate to severe exacerbations, all-cause mortality, major adverse cardiovascular events, or pneumonia.
• The population types studied included symptomatic patients with COPD from the Chinese National Healthcare System, stable COPD patients followed for 48 weeks, and moderate-to-severe COPD patients, with findings indicating that UMEC/VI was cost-effective and clinically efficacious in symptomatic COPD patients, while LABA/LAMA combinations, including UMEC/VI, were more effective than ICS/LABA fixed-dose combinations in improving FEV1 for moderate-to-severe COPD patients.